ACUTE MYELOID LEUKEMIA (AML)

This study tests whether the drug gilteritinib works better than sorafenib at keeping leukemia from coming back in people with a specific genetic mutation (FLT3-ITD) after a stem cell transplant. About 594 participants will be randomly assigned to take one of the two drugs for up…

This early-phase study tests a new type of immune cell therapy (supCD7 CART) for people with relapsed or hard-to-treat blood cancers that carry a specific marker called CD7. The therapy uses specially engineered cells to target and destroy cancer cells. Up to 12 adults aged 18 to…

This early-stage study tests an experimental drug called APL-4098, alone or with standard chemotherapy drugs, in about 100 adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to treatment. The main goals are to check safety, find…

This study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in adults with blood cancers who are at high risk of rejecting a stem cell transplant. Participants receive the drug before standard transplant preparation to reduce DSA levels enough to al…

This study tests whether adding metal-detoxifying drugs (Ca-EDTA and DMSA) to standard chemotherapy can help control acute myeloid leukemia (AML) in adults. Researchers believe that lowering certain metals in the blood and bone marrow may improve how well the cancer responds to t…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or not responded to standard therapy. Participants receive donor immune cells (NK cells) that are engineered to better target cancer, along with chemoth…

This early-phase study tests a new treatment called A-CAR028 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) to attack the cancer. The main goals are to check …

This study uses a cord blood transplant after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. About 200 participants will receive the transplant to see if it improves survival one year later. The approach aims to replace diseased bone …

This study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people with a specific IDH1 gene mutation. About 75 participants will receive either ivosidenib or a placebo for up to tw…

This early-stage study tests a new drug called STX-0712 in people with advanced types of leukemia (CMML or AML) that have not responded to other treatments. The main goals are to find a safe dose and check for side effects. About 105 adults will take part in this first-in-human t…

This early-stage trial tests niclosamide (a drug used for tapeworm infections) combined with standard chemotherapy in children whose acute myeloid leukemia (AML) has returned or not responded to prior treatments. The main goal is to find a safe dose and check for side effects. Up…

This study tests whether adding an experimental drug called ziftomenib to standard chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) live longer or achieve remission. About 1,300 adults with untreated AML and certain gene changes will receive …

This study tests a new combination of drugs (bendamustine and cyclophosphamide) to prevent graft-versus-host disease and a dangerous immune reaction after stem cell transplants. It involves 60 adults with high-risk blood cancers who have a partially matched donor. The goal is to …

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This study tests a new way to prepare patients with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) for a stem cell transplant. Instead of standard radiation, they receive targeted proton radiation to the bone marrow, aiming to reduce side effects. About …

This study tests the safety of combining ivosidenib and azacitidine in adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (IDH1-mutated) who cannot receive intensive chemotherapy. About 245 participants will receive the drug combination. The goal is …

This study is for adults with acute myeloid leukemia (AML) that has come back or not responded to treatment, and who have specific changes in their FLT3 and IDH genes. The researchers are testing whether combining two targeted drugs (gilteritinib with ivosidenib or enasidenib) is…

This study tests a combination of three drugs (venetoclax, a hypomethylating agent, and low-dose cytarabine) in adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated) who cannot tolerate strong chemotherapy. The goal is to see if this tre…

This program provides early access to venetoclax, a targeted therapy for several blood cancers including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and multiple myeloma. It is for people who have no other suitable treatments and cannot join a clinical trial…

This early-phase study tests a new treatment called universal CD7 CART cells for people with certain blood cancers (acute myeloid leukemia or T-cell leukemia/lymphoma) that have come back or not responded to standard therapy. The treatment uses donor immune cells modified to targ…

This study tests whether two drugs, azacitidine and venetoclax, can eliminate or reduce tiny amounts of leukemia that remain after standard chemotherapy in adults with acute myeloid leukemia (AML). Participants will receive the drug combination before undergoing a donor stem cell…

This study is a large registry that will follow up to 50,000 adults with acute myeloid leukemia (AML) or related blood cancers for up to 10 years. Researchers will collect medical history, genetic markers, and treatment outcomes to better understand the disease and improve future…

This study is a registry that collects information from 1,000 patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will track their health, treatments, and costs over time to learn how high altitude affects recover…

This study will follow 5,000 adults with acute myeloid leukemia (AML) in France to see how they are treated in everyday medical practice and how they fare over time. Researchers will track survival and disease-free periods for up to 10 years. The goal is to learn from real-life e…

This study is a registry that gathers medical information and blood samples from up to 15,000 adults with acute myeloid leukemia (AML) across 60 hospitals in Germany. The goal is to track patient characteristics, treatments, and outcomes like survival and relapse rates. No new dr…

This observational study looks at whether leukemia stem cells can help predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will measure these stem cells in bone marrow samples taken during regular check-ups. The goal is to improve relapse pr…

This study looks at whether a highly sensitive blood test (digital PCR) can find tiny amounts of leukemia cells left after a stem cell transplant. Researchers will follow 100 patients with acute myeloid leukemia for 12 months after transplant, checking their blood at set times. T…